SAN FRANCISCO--(BUSINESS WIRE)--Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced that Alice Zhang, CEO and co-founder of Verge Genomics, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 11:30 AM (PT).
Onsite:
Presentation: Thursday, January 12
Where: Mission Bay (32nd floor), The Westin St. Francis, San Francisco
Time: 11:30 AM - 11:55 AM (PT)
Presenter: Alice Zhang, CEO and co-founder, Verge Genomics
About Verge Genomics
Verge uses AI and human data to develop better drugs faster for the most challenging diseases of our generation. Verge has built CONVERGE™, an end-to-end drug discovery and development platform, that integrates multiple technological innovations from discovery to translation to streamline drug development. Its pioneering use of the industry’s most advanced all-in-human, AI-powered drug discovery platform identifies new medicines more efficiently and with an improved probability of success.
Verge is one of the first AI-enabled drug discovery companies to independently develop a clinical candidate from a novel target discovered from its platform. Verge has further demonstrated the power of CONVERGE™ by delivering a broad pipeline spanning diverse therapeutic areas, with its first program, an investigational PIKfyve inhibitor for the treatment of ALS, now in the clinic. The company is led by experienced drug developers and computational biologists with a shared belief that technology has created a new opportunity to deliver life-changing medicines more efficiently.
For additional information, please visit VergeGenomics.com. Follow us on LinkedIn and Twitter.
